SCHEMBL3399807

SCHEMBL3399807

CCOC(=O)c1sc(Cl)nc1-c1cc(OC)ccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 10/20 0.51
DBF4 Q9UBU7 10/20 0.51
LMNA P02545 2/20 0.45
PTPN11 Q06124 1/20 0.43
CCR1 P32246 1/20 0.43
CCR5 P51681 1/20 0.43
CCR8 P51685 1/20 0.43
DHODH Q02127 2/20 0.42
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
PPARG P37231 1/20 0.41
RAB9A P51151 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HSD17B10 Q99714 2/20 0.41
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3406257 0.86 ALDH1A1 (0.58) CDC7DBF4LMNACCR1CCR5
SCHEMBL3403482 0.82 LMNA (0.62) CDC7DBF4LMNADHODHNPC1
SCHEMBL510314 0.80 CDC7 (0.62) CDC7DBF4LMNANPC1MAPT
SCHEMBL3406836 0.79 CDC7 (0.48) CDC7DBF4LMNAMAPTALDH1A1
SCHEMBL1505433 0.76 LMNA (0.48) CDC7DBF4LMNADHODHMAPT
SCHEMBL3400633 0.76 NOTUM (0.40) CDC7DBF4LMNADHODHMAPT
SCHEMBL3402018 0.76 ALDH1A1 (0.52) CDC7DBF4LMNADHODHNPC1
SCHEMBL3403886 0.76 CDC7 (0.43) CDC7DBF4LMNADHODHMAPT
SCHEMBL11159408 0.74 MAPT (0.62) CDC7DBF4LMNAPTPN11DHODH
SCHEMBL3893108 0.74 ALDH1A1 (0.71) CDC7DBF4DHODHPPARGNCOA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 NISCH, PIR, QDPR CDC7 4571/4885DBF4 3986/4885LMNA 2265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.